Alternative Funding Task Force; create from members of the Mississippi Rare Disease Advisory Council.
Summary
SB 2757 creates a temporary Mississippi task force to study alternative funding programs and their effect on patient access to affordable prescription drugs. The task force is made up of the Mississippi Rare Disease Advisory Council members, or their designees, and is chaired by the council member who is a practicing physician with rare disease experience. It must begin meeting by May 15, 2025, and is directed to examine the prevalence, business model, and effects of alternative funding programs on prescription drug access, patient assistance programs, and insurance coverage.
The study is required to be completed by December 1, 2025. At that time, the task force must send copies of its study to specified medical, pharmacy, business, and pharmaceutical organizations, and submit a written report with any legislative recommendations to the Governor, the Division of Medicaid, and several House and Senate committees. The task force terminates once the study is submitted, so the bill creates no permanent agency or ongoing program.
Impact
The bill does not directly change Medicaid, insurance, or pharmacy law; instead, it creates a short-term advisory body to gather information and recommend possible future legislation. Its practical effect is to place the issue of alternative funding programs, prescription drug affordability, and coverage practices before state health policymakers and stakeholders, with the potential to influence later statutory or regulatory changes affecting commercial plans, public employee coverage, and exchange plans.
Sentiment
The bill appears generally informational and policy-oriented rather than adversarial. By using the Rare Disease Advisory Council as the task force base, it signals concern for patients who rely on costly or medically necessary drugs and suggests interest in preserving access to patient assistance programs. The absence of recorded committee debate or votes in the provided materials means there is no documented public opposition or support in the record here, but the structure of the bill suggests a consensus-building study approach.
Contention
The main substantive issue is the role of alternative funding programs in prescription drug coverage. Supporters are likely to view the study as a way to protect access to affordable medications and to understand whether these programs help or undermine patient assistance efforts. Potential critics may include pharmacy benefit managers, insurers, or employers if they believe alternative funding programs are a cost-management tool that should not be restricted, while independent pharmacies and patient advocates may be concerned about disruptions to coverage and assistance programs. The bill itself does not resolve these disputes; it sets up a forum to evaluate them and possibly recommend legislation.